📖 Approx. 8 minutes ／ Updated 2026.05.08
Key to Successful Medical Corporation M&A: Understanding Business Value from Financial Statements
M&A and business succession for medical corporations involve more than just transferring an organization; they entail multifaceted responsibilities such as the continuity of medical services, maintaining employee employment, and contributing to regional healthcare. Particularly, financial due diligence (DD) is one of the most critical processes that determines the success or failure of a transaction for both the seller and the buyer. Financial statements are a mirror reflecting the past business performance, financial status, and cash flow situation of a medical corporation, and without their detailed analysis, an appropriate M&A strategy cannot be formulated. This article provides an in-depth explanation from an expert’s perspective on how to read financial statements in medical corporation M&A, focusing on 15 key checkpoints that both sellers and buyers should pay attention to. It delves into issues unique to the healthcare industry, such as off-balance sheet liabilities, related-party transactions, and the appropriateness of medical fees, offering practical knowledge for successful M&A.
1. Identifying Hidden Liabilities and Assets from the Balance Sheet (B/S)
The balance sheet is a fundamental financial statement for understanding the financial status of a medical corporation at a specific point in time. In M&A, it is extremely important to analyze not only the surface figures but also their details and accompanying notes. Of particular note is “Accrued Medical Receivables.” This refers to claims for medical services rendered but not yet paid by social insurance, national health insurance organizations, etc. It is necessary to confirm whether these are unlikely to be collected or if they are overstated. Furthermore, regarding inventories of pharmaceuticals and medical supplies, verification against physical inventory counts and consideration of potential valuation losses due to deterioration or obsolescence are required. For leased assets and liabilities, it is essential to check for the existence of off-balance sheet transactions (transactions not recorded on the B/S) and to review the contract terms. Additionally, retirement benefit reserves are provisions set aside to prepare for future retirement payments to employees, but accurately grasping their calculation basis and future cash outflow is crucial for post-M&A management planning. In medical corporations, retirement benefit systems for professionals such as doctors and nurses can often be complex, requiring detailed examination by specialists.
2. Examining Profitability and Cost Structure Appropriateness in the Income Statement (P/L)
The income statement shows the business performance of a medical corporation over a certain period. Detailed analysis of the revenue breakdown (inpatient, outpatient, vaccinations, health checkups, etc.) is necessary to check for revenue source concentration or over-reliance on specific medical departments. Personnel expenses generally account for the largest portion of a medical corporation’s costs. Their appropriateness should be judged by comparing employee numbers, salary levels by position, and regional market rates. In particular, confirming whether executive and director compensation deviates significantly from market rates or shows unnatural fluctuations is important from the perspective of post-M&A operational efficiency. The material cost ratio (pharmaceuticals, medical supplies, etc.) reflects the appropriateness of procurement prices and the efficiency of usage. An excessively high material cost ratio may indicate improper procurement channels or issues with inventory management. For depreciation expenses, it is important to ensure the depreciation method for fixed assets such as medical equipment and buildings is appropriate, and to grasp the unamortized balance. This information is essential for forecasting future capital investment plans and the costs of replacement due to aging assets.
3. Grasping the Reality of Cash Flow from the Cash Flow Statement (C/F)
The cash flow statement presents the movement of funds of a medical corporation, categorized into three activities: “Operating Activities,” “Investing Activities,” and “Financing Activities.” In M&A, grasping the reality of “Cash Flow from Operating Activities” is particularly important. If there is a significant discrepancy between the profit on the income statement and operating CF, it may raise suspicions of window dressing or improper accounting practices. For example, if increases in accounts receivable and inventories are occurring at a faster pace than profits, there may be issues with the actual profitability or collection capabilities. Furthermore, the level of working capital is determined by the balance of cash and deposits, accounts receivable, accounts payable, and inventories required for daily business operations. Excessive working capital may indicate inefficient use of funds, while insufficient working capital suggests a risk of deteriorating cash flow. For cash flow from investing activities, the appropriateness of capital expenditures should be verified. It is important to examine whether investments for updating aging medical equipment or expanding future business are being made appropriately, and also to scrutinize excessive capital expenditures or the presence of idle assets from the perspective of post-M&A operational efficiency.
4. Identifying Potential Risks in Notes to Financial Statements and Related Party Reports
In addition to the financial statements themselves, the accompanying notes and the related party reports based on medical corporation accounting standards are crucial information sources in M&A due diligence. The notes disclose information such as related-party transactions (transactions with companies managed by the director’s family or their relatives, real estate lease agreements, etc.), contingent liabilities (lawsuits, pending cases, etc.), subsequent events (significant events occurring after the balance sheet date), significant accounting policies, and the basis for recording provisions. This information highlights risks not visible in the surface financial statements. Transactions with the director personally or related companies, in particular, require careful consideration regarding whether they are conducted at fair market prices and whether they will continue or be terminated after the M&A. Related party reports provide information on continuous transactions or transactions with a control-subordinate relationship between the medical corporation and related businesses that cannot be identified through individual transactions alone, detailing their content, amounts, and terms. Scrutinizing these reports and confirming whether there are deviations from market prices or if contracts are properly documented can help avoid future cost increases and risks associated with unfavorable transaction terms.
5. Consideration Received for Transfer Price and Taxation Options
The method of receiving consideration in M&A significantly impacts the seller’s tax burden. The main options include receiving it as a “transfer of equity stake” or as “retirement income.” When equity stakes are transferred, the capital gains are generally treated as capital gains and are subject to separate taxation (income tax 15.315% + resident tax 5% = total 20.315%). This is generally considered the most advantageous taxation method as it is not aggregated with other income, thus avoiding the impact of progressive taxation. On the other hand, it is also possible to receive part or all of the consideration as executive retirement benefits. Retirement income has a retirement income deduction based on years of service, and if the years of service are long, it may significantly reduce the tax burden. However, since retirement income may be subject to comprehensive taxation after the application of the “1/2 taxation” rule, it is necessary to carefully assess the advantages and disadvantages on a case-by-case basis. Receiving it as dividend income or salary income is subject to comprehensive taxation, with a top marginal tax rate of 55% (income tax + resident tax + business tax), making it generally the least favorable option. In designing the M&A scheme, it is crucial to collaborate with tax professionals to select the optimal method of receipt to minimize future tax burdens.
| Receipt Method | Taxation Method | Estimated Tax Rate | Advantage/Disadvantage |
|---|---|---|---|
| Transfer of Equity Stake | Separate Taxation | 20.315% | ★Advantageous |
| Executive Retirement Benefits | Retirement Income Deduction / 1/2 Taxation | Case-dependent (Advantageous if long service years) | Potentially Advantageous |
| Dividend/Salary Income | Comprehensive Taxation | Up to 55% | × Disadvantageous |
6. Organizing Financial Statements and Preparation for M&A Execution
To ensure successful M&A, it is important not only to scrutinize the content of financial statements but also to organize them and reduce potential risks before M&A execution. Specifically, unnecessary related-party transactions (such as those with the director personally or related companies that offer no benefit to continue after the M&A) should be settled through contract termination or renegotiation of terms. This simplifies the financial structure after M&A and facilitates management. For inventories, excess or obsolete stock should be optimized, and valuation losses should be recognized to reflect the actual asset value. For fixed assets, measures such as selling idle assets or assets with low utilization rates should be considered to improve asset efficiency. In particular, for aging medical equipment, the costs of replacement must be accurately assessed and incorporated into the post-M&A capital investment plan. For retirement benefit obligations, it is necessary to fulfill the responsibility to explain to employees, finalize future cash outflows, and incorporate them into the post-M&A financial plan. These organizational efforts not only facilitate smooth M&A due diligence but also enhance credibility with the buyer, potentially leading to more favorable M&A negotiation terms.
7. The Importance of Collaboration with Experts in Medical M&A
M&A and business succession for medical corporations require advanced specialized knowledge due to their unique nature. Numerous issues differ from general corporate M&A, including the medical fee system, the organizational forms of medical corporations (corporate medical organizations, foundation medical organizations), the existence of equity stakes, fund systems, general meetings of members, impact on regional healthcare plans, and the transfer of licenses and permits. Throughout the entire process, from detailed analysis of financial statements, identification of potential risks such as off-balance sheet and contingent liabilities, consideration of optimal methods for receiving transfer consideration, to the formulation of post-M&A management strategies, collaboration with a team of experts is indispensable. This includes tax accountants, certified public accountants, lawyers, and M&A intermediaries specializing in medical M&A. In particular, M&A Medical, operated by CentralMedience Inc., a certified M&A support institution by the Small and Medium Enterprise Agency, possesses specialized knowledge and extensive experience in the healthcare industry, providing meticulous support from both seller and buyer perspectives. They offer comprehensive support for the entire M&A process, from detailed financial statement analysis, scheme structuring, price negotiation, contract execution, to post-succession integration support, facilitating smooth and successful M&A. Please feel free to contact us for an initial consultation.
For Medical Succession Consultations, Contact M&A Medical
M&A Medical is a specialized M&A and business succession support service for medical institutions. As an M&A support institution certified by the Small and Medium Enterprise Agency, we support the success of transfers for clinics and medical corporations facing successor shortages, as well as strategic acquisitions, on a success-fee basis.
- Initial consultation and preliminary assessment are free
- No upfront fees or monthly charges (success fee only)
- Strict confidentiality (proceeds under NDA)
- Services available nationwide across all 47 prefectures and all medical specialties
Please consult with us early in your consideration phase, whether you are “just curious about market value,” “have no successor,” or are “considering joining a group.”